| ²é¿´: 381 | »Ø¸´: 1 | |||
abcd888898Òø³æ (ÕýʽдÊÖ)
|
[½»Á÷]
Bydureon™ Receives Marketing Authorization in Europe ÒÑÓÐ1È˲ÎÓë
|
|
INDIANAPOLIS, SAN DIEGO and WALTHAM, Mass., June 21, 2011 /PRNewswire via COMTEX/ -- Eli Lilly and Company (NYSE: LLY), together with Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Alkermes, Inc. (Nasdaq: ALKS), announced today that the European Commission has granted marketing authorization to BYDUREON(TM) (exenatide 2 mg powder and solvent for prolonged release suspension for injection). BYDUREON, a glucagon-like peptide-1 (GLP-1) receptor agonist, is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione. |
» ²ÂÄãϲ»¶
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
2026Äêɽ¶«´óѧº£ÑóѧԺÉúÎïÓëÒ½Ò©²©Ê¿ÕÐÉú-Àîϼ¿ÎÌâ×é
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ96È˻ظ´
²©Ê¿Ñо¿ÉúÕÐÉú
ÒѾÓÐ0È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Ò©Àíѧ¡¢ÁÙ´²Ò©Ñ§·½Ïò µ÷¼Á
ÒѾÓÐ1È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
Funny English quiz in everyday£¨NO.7£©
ÒѾÓÐ28È˻ظ´
Austerity vs. Europe
ÒѾÓÐ3È˻ظ´
×î¾µäµÄ¹ÌÌåÎïÀíÖø×÷£ºCONCEPTS IN SOLIDS by P.W.Anderson
ÒѾÓÐ776È˻ظ´
¡¾ÇóÖú¡¿JPCMµÄ״̬in progressʲôÒâ˼£¿
ÒѾÓÐ5È˻ظ´
sahaiqiqi
½ð³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 449.6
- É¢½ð: 109
- ºì»¨: 11
- Ìû×Ó: 242
- ÔÚÏß: 53.4Сʱ
- ³æºÅ: 1306997
- ×¢²á: 2011-05-26
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
2Â¥2011-06-24 20:30:33














»Ø¸´´ËÂ¥